JP2007507514A5 - - Google Patents

Download PDF

Info

Publication number
JP2007507514A5
JP2007507514A5 JP2006534060A JP2006534060A JP2007507514A5 JP 2007507514 A5 JP2007507514 A5 JP 2007507514A5 JP 2006534060 A JP2006534060 A JP 2006534060A JP 2006534060 A JP2006534060 A JP 2006534060A JP 2007507514 A5 JP2007507514 A5 JP 2007507514A5
Authority
JP
Japan
Prior art keywords
alkyl
independently
members
substituent assignments
independent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006534060A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007507514A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/032003 external-priority patent/WO2005033088A1/en
Publication of JP2007507514A publication Critical patent/JP2007507514A/ja
Publication of JP2007507514A5 publication Critical patent/JP2007507514A5/ja
Pending legal-status Critical Current

Links

JP2006534060A 2003-09-30 2004-09-29 キノキサリン化合物 Pending JP2007507514A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50717603P 2003-09-30 2003-09-30
PCT/US2004/032003 WO2005033088A1 (en) 2003-09-30 2004-09-29 Quinoxaline compounds

Publications (2)

Publication Number Publication Date
JP2007507514A JP2007507514A (ja) 2007-03-29
JP2007507514A5 true JP2007507514A5 (enExample) 2007-11-22

Family

ID=34421591

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006534060A Pending JP2007507514A (ja) 2003-09-30 2004-09-29 キノキサリン化合物

Country Status (11)

Country Link
US (1) US20050070527A1 (enExample)
EP (1) EP1670774A1 (enExample)
JP (1) JP2007507514A (enExample)
KR (1) KR20060111466A (enExample)
CN (1) CN1886389B (enExample)
AU (2) AU2004278372B2 (enExample)
CA (1) CA2540638A1 (enExample)
IL (1) IL174629A0 (enExample)
MX (1) MXPA06003578A (enExample)
WO (1) WO2005033088A1 (enExample)
ZA (1) ZA200603410B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
ATE478067T1 (de) 2006-03-31 2010-09-15 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors
WO2007120690A2 (en) * 2006-04-10 2007-10-25 Janssen Pharmaceutica N.V. Combination histamine h1r and h4r antagonist therapy for treating pruritus
AU2007271187A1 (en) * 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Fused bicyclic compounds interacting with the histamine H4 receptor
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
US7985745B2 (en) 2006-10-02 2011-07-26 Abbott Laboratories Method for pain treatment
EP2077263A1 (en) * 2008-01-02 2009-07-08 Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg Quinazolines and related heterocyclic compounds and their therapeutic use
UA100567C2 (ru) * 2008-06-12 2013-01-10 Янссен Фармацевтика Нв Использование антагонистов н4-гистаминовых рецепторов для лечения послеоперационных спаек
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2201982A1 (en) 2008-12-24 2010-06-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Histamine H4 receptor antagonists for the treatment of vestibular disorders
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102762572A (zh) 2010-02-01 2012-10-31 诺瓦提斯公司 作为CRF-1受体拮抗剂的吡唑并[5,1b]*唑衍生物
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
EP2531490B1 (en) 2010-02-02 2014-10-15 Novartis AG Cyclohexyl amide derivatives as crf receptor antagonists
UY34094A (es) 2011-05-27 2013-01-03 Novartis Ag Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
WO2013164790A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
HUE039713T2 (hu) 2012-06-08 2019-02-28 Sensorion H4 receptor inhibitorok tinnitus kezelésére
JO3516B1 (ar) 2013-03-06 2020-07-05 Janssen Pharmaceutica Nv مُعدِّلات بنزإيميدازول-2-يل بيريميدين لمستقبل الهستامين h4
CN105001169B (zh) * 2015-07-09 2017-07-21 华侨大学 一种3‑氨基喹喔啉‑2(1h)‑酮类化合物的合成方法
CN110092760B (zh) * 2019-06-04 2020-11-13 杭州师范大学 一种3-氟代烷氧基-2(1h)-喹喔啉酮及其合成方法
KR20240057402A (ko) * 2021-07-23 2024-05-02 인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르 그람 음성 박테리아 유출 펌프 억제제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3493572A (en) * 1968-07-05 1970-02-03 Pfizer & Co C Process for producing quinoxaline-di-n-oxides
FI193974A7 (enExample) * 1973-07-13 1975-01-14 Merck & Co Inc
EP0008864A1 (en) * 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
DK716188D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Quinoxalinforbindelser, deres fremstilling og anvendelse
DE4342024A1 (de) * 1993-12-09 1995-06-14 Hoechst Ag Kombinationspräparate, enthaltend ein Chinoxalin und ein Nukleosid
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
DK1534391T3 (da) * 2002-07-19 2007-06-11 Biovitrum Ab Nye piperazinyl-pyrazinonderivater til behandling af 5-HT2A-recptor-relaterede forstyrrelser

Similar Documents

Publication Publication Date Title
CN1129581C (zh) 氰基苯基衍生物
ES2549087T3 (es) Derivados de aminodihidrotiazina como inhibidores de BACE para el tratamiento de la enfermedad de Alzheimer
DE69110320T2 (de) Stickstoff enthaltende heterozyklische Verbindungen, ihre Herstellung und Verwendung.
JP4853965B2 (ja) アダマンタン誘導体およびアザビシクロオクタン誘導体およびアザビシクロノナン誘導体、ならびにこれらの調製方法およびdpp−iv阻害剤としてのこれらの使用
CA2657702A1 (en) Quinazolines and related heterocyclic comp0unds, and their therapeutic use
JPS61152662A (ja) 新規な二環式複素アリールピペラジン化合物とその医薬並びにその製造法
RU2009113585A (ru) Производные дибензофурана в качестве ингибиторов pde-4 и pde-10
ES8203073A1 (es) Un procedimiento para la preparacion de etanaminas
HRP20041005A2 (en) Quinoline and isoquinoline derivatives, method forthe production thereof and use thereof as anti-inflammatory agents
KR20160111999A (ko) 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제
WO2004007471A1 (ja) N−フェニル−(2r,5s)ジメチルピペラジン誘導体
ME02672B (me) Fenil-3-aza-bicikl0[3.1.0]heks-3-il-metanoni i njihova primena kao medikament
MX2009000110A (es) Derivados de piperazinilo utiles en el tratamiento de enfermedades mediadas por el receptor grp38.
ZA200604395B (en) Novel M3 Muscarinic Acetylcholine receptor antagonists
JP2007524706A (ja) ピペリジニルアルキルカーバメートの誘導体、これらの製造方法及びfaah酵素インヒビターとしての使用
AU2006322185A1 (en) Trisubstituted quinazolinone derivatives as vanilloid antagonists
JP2014504648A5 (enExample)
JPH04182467A (ja) ジアリールメトキシピペリジン誘導体
JP7618642B2 (ja) インターロイキンの調節におけるプロドラッグ
JP2020517676A5 (enExample)
JPS58159480A (ja) 新規なフエニルピペラジン誘導体
RU2015114405A (ru) Замещенные соединения фенилкарбамата
JPS5840552B2 (ja) 1,4− ベンゾジオキサンノ アミンユウドウタイノセイホウ
JPS59101470A (ja) 2−ピペラジニルキナゾリン誘導体、その製法および医薬
JPS5988467A (ja) フエノキシアミノプロパノ−ル誘導体